Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Becton Dickinson and Co / Equity Bottom-Up

<ul><li>Becton, Dickinson and Company (BD) reported its fourth-quarter and full-year fiscal 2025 results with several notable highlights and challenges, providing insights into its financial performance and future strategy.</li><li>On the positive side, BD's fourth-quarter revenue increased to $5.9 billion, a 7% year-over-year increase, and a 3.9% organic growth.</li><li>For the full year, BD achieved a record revenue of $21.8 billion, marking a 7.7% increase, with a 2.9% organic growth.</li></ul>

Becton, Dickinson and Company (BD) reported its fourth-quarter and full-year fiscal 2025 results with several notable highlights and challenges, providing insights into its financial performance and future strategy.On the positive side, BD's fourth-quarter revenue increased to $5.9 billion, a 7% year-over-year increase, and a 3.9% organic growth.For the full year, BD achieved a record revenue of $21.8 billion, marking a 7.7% increase, with a 2.9% organic growth.

Becton Dickinson: Pharmaceutical Systems & Core Medical Consumables as Durable Growth Anchors!

Founder at Stock Spin-off Investing, Stock Spin-Off Investing

Richard Howe

Founder at Stock Spin-off Investing

Stock Spin-Off Investing

Generate attractive returns by taking advantage of inefficiencies in the stock spin-off market.

Stock Spin-offs

<ul><li>In Q1 2026, BDX will merge its Biosciences &amp; Diagnostic Solutions segment to Waters (WAT). BDX will receive $4BN in cash and 0.14 WAT shares per BDX share, leaving its shareholders with roughly 39 percent of the combined company.</li><li>The remaining business, referred to as New BD, will be a focused med-tech company with ~$18BN in revenue across Medical Essentials, Connected Care, BioPharma Systems, and Interventional. More than 90 percent of revenue will be recurring, and management expects high single-digit earnings growth.</li><li>New BD’s valuation looks appealing. Based on where BDX and WAT currently trade, New BD implies a P/E of roughly 11x earnings. I believe the business deserves at least a 13x multiple, which would equate to about 12% upside. That said, I’m not ready to buy yet.</li></ul>

In Q1 2026, BDX will merge its Biosciences &amp; Diagnostic Solutions segment to Waters (WAT). BDX will receive $4BN in cash and 0.14 WAT shares per BDX share, leaving its shareholders with roughly 39 percent of the combined company.The remaining business, referred to as New BD, will be a focused med-tech company with ~$18BN in revenue across Medical Essentials, Connected Care, BioPharma Systems, and Interventional. More than 90 percent of revenue will be recurring, and management expects high single-digit earnings growth.New BD’s valuation looks appealing. Based on where BDX and WAT currently trade, New BD implies a P/E of roughly 11x earnings. I believe the business deserves at least a 13x multiple, which would equate to about 12% upside. That said, I’m not ready to buy yet.

New BD Looks Cheap But I’m Not Ready to Buy (Yet)

<ul><li>Becton, Dickinson and Company (BD) reported its third fiscal quarter results for 2025, highlighting both positive developments and challenges within the company.</li><li>BD's revenue grew by 8.5% to $5.5 billion, with organic growth at 3%.</li><li>The adjusted gross margin increased by 50 basis points year-over-year to 54.8%, and the adjusted operating margin improved by 60 basis points to 25.8%.</li></ul>

Becton, Dickinson and Company (BD) reported its third fiscal quarter results for 2025, highlighting both positive developments and challenges within the company.BD's revenue grew by 8.5% to $5.5 billion, with organic growth at 3%.The adjusted gross margin increased by 50 basis points year-over-year to 54.8%, and the adjusted operating margin improved by 60 basis points to 25.8%.

Becton Dickinson Fuels Biologics Boom With 70+ GLP-1 Agreements; What Lies Ahead?

<ul><li>Becton, Dickinson and Company (BD) recently held its first quarter fiscal 2025 earnings presentation, announcing strong financial performance and strategic decisions that could significantly reshape the company’s future.</li><li>The most critical updates included the impressive results from its existing business units, plans to separate its Biosciences and Diagnostic Solutions segment, and supporting market prospects driven by ongoing innovation.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

Becton, Dickinson and Company (BD) recently held its first quarter fiscal 2025 earnings presentation, announcing strong financial performance and strategic decisions that could significantly reshape the company’s future.The most critical updates included the impressive results from its existing business units, plans to separate its Biosciences and Diagnostic Solutions segment, and supporting market prospects driven by ongoing innovation.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

Becton Dickinson: 85% Recurring Revenue—Is This Stock an Untouchable Healthcare Powerhouse?

Event-Driven

<ul>
<li>Honeywell International (HON) announced its plan to spin off its Advanced Materials business on October 8, 2024.</li>
<li>Subsequently, on February 6, 2025, the company revealed its intention to separate into three independent entities by also spinning off its Aerospace and Automation divisions.</li>
<li>Automation (49% of revenue): This segment will concentrate on developing advanced automation technologies.</li>
</ul>


Honeywell International (HON) announced its plan to spin off its Advanced Materials business on October 8, 2024.
Subsequently, on February 6, 2025, the company revealed its intention to separate into three independent entities by also spinning off its Aerospace and Automation divisions.
Automation (49% of revenue): This segment will concentrate on developing advanced automation technologies.


United States

Becton, Dickinson and Company is a global medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Becton Dickinson and Co (BDX US)

Becton Dickinson: Pharmaceutical Systems & Core Medical Consumables as Durable Growth Anchors!

Becton, Dickinson and Company (BD) reported its fourth-quarter and full-year fiscal 2025 results with several notable highlights and challenges,...

Baptista Research

New BD Looks Cheap But I’m Not Ready to Buy (Yet)

In Q1 2026, BDX will merge its Biosciences & Diagnostic Solutions segment to Waters (WAT). BDX will receive $4BN in cash and 0.14 WAT shares...

Richard Howe

Becton Dickinson Fuels Biologics Boom With 70+ GLP-1 Agreements; What Lies Ahead?

Becton, Dickinson and Company (BD) reported its third fiscal quarter results for 2025, highlighting both positive developments and challenges...

Baptista Research

Becton Dickinson: 85% Recurring Revenue—Is This Stock an Untouchable Healthcare Powerhouse?

Becton, Dickinson and Company (BD) recently held its first quarter fiscal 2025 earnings presentation, announcing strong financial performance and...

Baptista Research

Weekly Update (MRP, WDC, HON, LGFA)

Honeywell International (HON) announced its plan to spin off its Advanced Materials business on October 8, 2024. Subsequently, on February 6, 2025,...

Richard Howe

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)